Illumina, Inc.(ILMN) Stock Research - Grey Stern Research
Loading...

Illumina, Inc. (ILMN) Stock Analysis

$140.36 (-0.67%)

ILMN Financial Performance


Use the table below to view Illumina, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $140.36 -
52 Week Low $97.36 -
52 Week High $156.66 -
Market Cap $22.3 Billion 7/10
Gross Margin 69% 3/10
Profit Margin 65% 1/10
EBITDA margin 76% 1/10
Q3 - 2024 Revenue $1.1 Billion 4/10
Q3 - 2024 Earnings $705.0 Million 3/10
Q3 - 2024 Free Cash Flow $284.0 Million 3/10
Trailing 4 Quarters Revenue $4.4 Billion 4/10
Trailing 4 Quarters Earnings -$1.6 Billion 10/10
Quarterly Earnings Growth 194% 1/10
Annual Earnings Growth -9% 8/10
Quarterly Revenue Growth -3% 9/10
Annual Revenue Growth -6% 10/10
Cash On Hand $869.0 Million 5/10
Short Term Debt $73.0 Million 6/10
Long Term Debt $2.6 Billion 4/10

Illumina, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Illumina, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 6/10
PS 5.07 8/10
PB 9.13 4/10
PC 25.62 6/10
Liabilities to Equity 1.47 2/10
ROA -0.26 8/10
ROE -0.65 10/10
Current Ratio 1.68 9/10
Quick Ratio 0.26 5/10
Long Term Debt to Equity 1.07 1/10
Debt to Equity 1.07 1/10
Burn Rate -1.49 7/10
Cash to Cap 0.04 4/10
CCR 0.40 5/10
EV to EBITDA 29.05 7/10
EV to Revenue 5.47 8/10

Company Details

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

CEO: Mr. Francis deSouza

Website: https://www.illumina.com

Address: 5200 Illumina Way San Diego, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Diagnostics & Research

Illumina, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Illumina, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
CareDx, Inc CDNA $1.2 Billion
Agilent Technologies, Inc. A $43.6 Billion
Danaher Corporation DHR $176.4 Billion
Thermo Fisher Scientific Inc. TMO $219.8 Billion
Exact Sciences Corporation EXAS $10.1 Billion
IDEXX Laboratories, Inc. IDXX $35.3 Billion
Waters Corporation WAT $24.2 Billion
Natera, Inc. NTRA $22.7 Billion
Twist Bioscience Corporation TWST $3.1 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
ILMN Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 1.1 Billion $705.0 Million
Q2 2024 $ 1.1 Billion -$2.0 Billion
Q1 2024 $ 1.1 Billion -$126.0 Million
Q4 2023 $ 1.1 Billion -$176.0 Million
Q3 2023 $ 1.1 Billion -$754.0 Million
Q2 2023 $ 1.2 Billion -$234.0 Million
Q1 2023 $ 1.1 Billion $3.0 Million
Q4 2022 $ 1.1 Billion -$140.0 Million

View All

ILMN Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $869.0 Million $6.0 Billion $2.6 Billion $2.4 Billion
Q2 2024 $920.0 Million $6.1 Billion $2.9 Billion $1.4 Billion
Q1 2024 $1.1 Billion $10.0 Billion $2.3 Billion $5.7 Billion
Q4 2023 $1.0 Billion $10.1 Billion $687.0 Million $7.9 Billion
Q3 2023 $927.0 Million $10.1 Billion $2.2 Billion $5.9 Billion
Q2 2023 $1.6 Billion $11.8 Billion $1.5 Billion $8.0 Billion
Q1 2023 $1.5 Billion $11.8 Billion $3.0 Billion $6.7 Billion
Q4 2022 $2.0 Billion $12.3 Billion $3.5 Billion $6.6 Billion

View All

ILMN Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $284.0 Million -$32.0 Million -$51.0 Million
Q2 2024 $49.0 Million -$31.0 Million -$188.0 Million
Q1 2024 $41.0 Million -$36.0 Million $60.0 Million
Q4 2023 $173.0 Million -$51.0 Million $121.0 Million
Q3 2023 $94.0 Million -$45.0 Million -$626.0 Million
Q2 2023 $58.0 Million -$47.0 Million $59.0 Million
Q1 2023 -$42.0 Million -$52.0 Million -$517.0 Million
Q4 2022 $59.0 Million -$88.0 Million $1.0 Billion

View All